The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
Abstract
Butyrylcholinesterase (BChE) and an altered form of acetylcholinesterase (AChE) accumulate in the plaques and tangles of Alzheimer's disease (AD). The sources for these plaque‐ and tangle‐bound cholinesterases have not been identified. We now report that AChE and BChE activities with pH preferences and inhibitor selectivities identical to those of plaque‐ and tangle‐bound cholinesterases are found in the astrocytes and oligodendrocytes of control and AD brains. These glial‐type cholinesterases are selectively inhibited by indolamines and protease inhibitors. In control brains glial‐type cholinesterases appear confined to the intracellular space, whereas in patients with AD they decorate plaques and tangles as well. In control and AD brains AChE‐positive glia are distributed throughout the cortical layers and subcortical white matter, whereas BChE‐positive glia reach high densities only in the deep cortical layers and white matter. In non‐AD control brains, the ratio of BChE to AChE glia was higher in entorhinal and inferotemporal cortex, two regions with a high susceptibility to the pathology of AD, than in primary somatosensory and visual cortex, two areas with a relatively lower susceptibility to the disease process. There were no age‐related differences in the density or distribution of cholinesterase‐positive glia. In comparison with age‐matched control specimens, AD brains had a significantly higher density of BChE glia and a lower density of AChE glia in entorhinal and inferotemporal regions but not in the primary somatosensory or visual areas. These results suggest that glia constitute a likely source for the cholinesterase activity of plaques and tangles and that a high ratio of BChE‐ to AChE‐positive glia may play a permissive or causative role in the neuropathology of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.
Busciglio, J., Gabuzda, D. H., Matsudaira, P., & Yankner, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2092 · Cited by 569
Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314
Cited by
Acetylcholinesterase — new roles for an old actor
Soreq, H., & Seidman, S. (2001) · Nature Reviews Neuroscience · doi:10.1038/35067589 · Cited by 1,390
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1035 · Cited by 891
Self-citationTargeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Mesulam, M.-M., Guillozet, A., Shaw, P., Levey, A., Duysen, E. G., & Lockridge, O. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00613-3 · Cited by 650
Self-citation
Metadata
- Authors
- Wright, C. I., Geula, C., & Mesulam, M. ‐.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1993-09
- Volume
- 34
- Issue
- 3
- Pages
- 373-384
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2135336998
- Cited by
- 219
- References
- 4
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.